vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and OXFORD INDUSTRIES INC (OXM). Click either name above to swap in a different company.
OXFORD INDUSTRIES INC is the larger business by last-quarter revenue ($307.3M vs $284.0M, roughly 1.1× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -20.7%, a 117.1% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -0.2%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -3.0%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Oxford Industries, Inc. is a publicly traded clothing company in the United States that specializes in high-end clothing and apparel. The company carries many major labels, including Tommy Bahama, Lilly Pulitzer, Johnny Was and Southern Tide.
ACAD vs OXM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $307.3M |
| Net Profit | $273.6M | $-63.7M |
| Gross Margin | 90.8% | 60.3% |
| Operating Margin | 6.1% | -27.7% |
| Net Margin | 96.3% | -20.7% |
| Revenue YoY | 9.4% | -0.2% |
| Net Profit YoY | 90.3% | -1517.6% |
| EPS (diluted) | $1.61 | $-4.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $307.3M | ||
| Q3 25 | $278.6M | $403.1M | ||
| Q2 25 | $264.6M | $392.9M | ||
| Q1 25 | $244.3M | — | ||
| Q4 24 | $259.6M | $308.0M | ||
| Q3 24 | $250.4M | $419.9M | ||
| Q2 24 | $242.0M | $398.2M | ||
| Q1 24 | $205.8M | $404.4M |
| Q4 25 | $273.6M | $-63.7M | ||
| Q3 25 | $71.8M | $16.7M | ||
| Q2 25 | $26.7M | $26.2M | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $143.7M | $-3.9M | ||
| Q3 24 | $32.8M | $40.6M | ||
| Q2 24 | $33.4M | $38.4M | ||
| Q1 24 | $16.6M | $-60.1M |
| Q4 25 | 90.8% | 60.3% | ||
| Q3 25 | 92.2% | 61.4% | ||
| Q2 25 | 92.2% | 64.2% | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | 63.1% | ||
| Q3 24 | 92.5% | 63.1% | ||
| Q2 24 | 92.5% | 64.9% | ||
| Q1 24 | 88.8% | 60.9% |
| Q4 25 | 6.1% | -27.7% | ||
| Q3 25 | 12.8% | 6.3% | ||
| Q2 25 | 12.2% | 9.2% | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | -2.0% | ||
| Q3 24 | 12.6% | 12.5% | ||
| Q2 24 | 12.6% | 13.2% | ||
| Q1 24 | 7.4% | -20.1% |
| Q4 25 | 96.3% | -20.7% | ||
| Q3 25 | 25.8% | 4.1% | ||
| Q2 25 | 10.1% | 6.7% | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 55.4% | -1.3% | ||
| Q3 24 | 13.1% | 9.7% | ||
| Q2 24 | 13.8% | 9.6% | ||
| Q1 24 | 8.0% | -14.9% |
| Q4 25 | $1.61 | $-4.28 | ||
| Q3 25 | $0.42 | $1.12 | ||
| Q2 25 | $0.16 | $1.70 | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | $-0.25 | ||
| Q3 24 | $0.20 | $2.57 | ||
| Q2 24 | $0.20 | $2.42 | ||
| Q1 24 | $0.10 | $-3.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $8.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $528.0M |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $8.0M | ||
| Q3 25 | $258.0M | $6.9M | ||
| Q2 25 | $253.6M | $8.2M | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | $7.0M | ||
| Q3 24 | $155.1M | $18.4M | ||
| Q2 24 | $177.1M | $7.7M | ||
| Q1 24 | $204.7M | $7.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $29.0M |
| Q4 25 | $1.2B | $528.0M | ||
| Q3 25 | $917.3M | $597.1M | ||
| Q2 25 | $822.4M | $592.4M | ||
| Q1 25 | $765.2M | — | ||
| Q4 24 | $732.8M | $612.2M | ||
| Q3 24 | $577.2M | $621.6M | ||
| Q2 24 | $516.7M | $592.9M | ||
| Q1 24 | $464.0M | $560.9M |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $976.9M | $1.2B | ||
| Q2 24 | $914.1M | $1.2B | ||
| Q1 24 | $855.1M | $1.1B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.05× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $-9.1M |
| Free Cash FlowOCF − Capex | — | $-47.9M |
| FCF MarginFCF / Revenue | — | -15.6% |
| Capex IntensityCapex / Revenue | — | 12.6% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-79.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $-9.1M | ||
| Q3 25 | $74.3M | $83.5M | ||
| Q2 25 | $64.0M | $-3.9M | ||
| Q1 25 | $20.3M | — | ||
| Q4 24 | $40.4M | $-18.2M | ||
| Q3 24 | $63.2M | $88.8M | ||
| Q2 24 | $25.0M | $32.9M | ||
| Q1 24 | $29.1M | $74.9M |
| Q4 25 | — | $-47.9M | ||
| Q3 25 | $73.9M | $52.3M | ||
| Q2 25 | — | $-27.4M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-56.9M | ||
| Q3 24 | $63.2M | $47.2M | ||
| Q2 24 | — | $21.0M | ||
| Q1 24 | — | $55.3M |
| Q4 25 | — | -15.6% | ||
| Q3 25 | 26.5% | 13.0% | ||
| Q2 25 | — | -7.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.5% | ||
| Q3 24 | 25.2% | 11.2% | ||
| Q2 24 | — | 5.3% | ||
| Q1 24 | — | 13.7% |
| Q4 25 | — | 12.6% | ||
| Q3 25 | 0.1% | 7.7% | ||
| Q2 25 | — | 6.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 12.6% | ||
| Q3 24 | 0.0% | 9.9% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 4.8% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 5.00× | ||
| Q2 25 | 2.40× | -0.15× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 2.19× | ||
| Q2 24 | 0.75× | 0.86× | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
OXM
| Sales Channel Retail | $162.9M | 53% |
| Sales Channel Wholesale | $61.3M | 20% |
| Johnny Was | $45.4M | 15% |
| Sales Channel Food And Beverage | $29.3M | 10% |
| Other Foreign Countries | $9.0M | 3% |
